It is noteworthy that for 131I of thyroid cancer, the oldest RPT that is still commonly practised worldwide, as well as for 177Lu-PSMA-RLT of prostate cancer, the new blockbuster RPT, prospective data for dosimetry-driven regimes is not yet available. Here, FOLH1 is linked to Familial prostate cancer.